StreetInsider.com News Articles

Form 4 Crinetics Pharmaceutical For: Jun 17 Filed by: Okey Stephanie

Thu, 18 Jun 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260618/26667346.html

Form 4 Crinetics Pharmaceutical For: Jun 17 Filed by: Okey Stephanie

Thu, 18 Jun 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260618/26667346.html

Form 144 Crinetics Pharmaceutical Filed by: Okey Stephanie

Wed, 17 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260617/26660298.html

Form 144 Crinetics Pharmaceutical Filed by: Okey Stephanie

Wed, 17 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260617/26660298.html

Crinetics (CRNX) Reiterated at Market Outperform by Citizens on ENDO Updates

Tue, 16 Jun 2026 05:12:35 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $95.00 price target on Crinetics (NASDAQ: CRNX).

The analyst commented, "CRNX took center stage at ENDO, with updates providing further support of Palsonify during its early launch phase in acromegaly, as well as updates for atumelnant in both CAH and Cushing’s. Palsonify continues to reinforce its best in class efficacy profile with durable ~twoyear OLE data validating it as a compelling alternative to long-acting injectable SSAs. Early launch dynamics remain highly encouraging, with ~$10M in 1Q sales (doubling Q/Q) and a steadily expanding prescriber base, supporting our view that the once-daily

H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)

Mon, 15 Jun 2026 06:48:04 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $81.00 price target on Crinetics (NASDAQ: CRNX).

The analyst commented: "Crinetics presented new long-term follow-up data from the PATHFNDR-1 and PATHFNDR-2 OLE studies at ENDO 2026, further supporting the durability of Palsonify's efficacy and safety profile. In PATHFNDR-1, which enrolled patients previously controlled on injectable SRLs, with baseline mean IGF-1 levels at 0.91x ULN at enrollment in OLE, their IGF-1 levels remained stable up to 96 weeks at 0.81x ULN. Pituitary tumor volumes remained stable in all patients at week 48 relative to the OLE baseline. PATHFNDR-2 enrolled adults with biochemically

Crinetics reports two-year PALSONIFY acromegaly treatment data

Mon, 15 Jun 2026 03:02:51 -0400

Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) presented long-term clinical data for its acromegaly treatment PALSONIFY at the Endocrine Society's Annual Meeting on June 14. The data covered up to two years of treatment from open-label extension studies of the PATHFNDR-1 and PATHFNDR-2 trials.

In the PATHFNDR-1 extension study, 53 patients who had switched from monthly injectable treatments maintained stable IGF-1 levels over 96 weeks. Baseline IGF-1 levels of 0.91 times the upper limit of normal remained at 0.81 times the upper limit at 96 weeks. All patients showed stable pituitary tumor volumes at 48 weeks.

The PATHFNDR-2 extension study included 114 patients with

Crinetics reports two-year PALSONIFY acromegaly treatment data

Mon, 15 Jun 2026 03:02:51 -0400

The PATHFNDR-2 extension study included 114 patients with

Crinetics presents CAH trial data for atumelnant at ENDO 2026

Sun, 14 Jun 2026 16:30:16 -0400

Crinetics Pharmaceuticals (NASDAQ: CRNX) presented results from its Phase 2 trial of atumelnant for congenital adrenal hyperplasia at the Endocrine Society's Annual Meeting ENDO 2026.

The trial tested atumelnant, an oral adrenocorticotropic hormone receptor antagonist, in adults with classic CAH. In Cohort 4, participants received 80 mg once daily, with glucocorticoid doses reduced stepwise beginning at week 2 to target physiologic levels.

At week 12, participants showed a mean 67% reduction in morning serum androstenedione levels from baseline. Seven of eight participants who completed 12 weeks achieved physiologic daily glucocorticoid doses. The treatment also produced sustained reductions in 11-OHA4 and 11-KT levels

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Sun, 14 Jun 2026 16:30:00 -0400

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

New results from the Phase 1b/2a ACTH-dependent Cushing’s syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower dose

SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented data today from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Sun, 14 Jun 2026 16:30:00 -0400

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Sun, 14 Jun 2026 14:45:00 -0400

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks

Additional ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and cabergoline combination improves biochemical control of acromegaly

SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced new long-term data from its clinical development program evaluating novel PALSONIFY^TM (paltusotine) in acromegaly during an oral presentation

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Sun, 14 Jun 2026 14:45:00 -0400

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks

Additional ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and cabergoline combination improves biochemical control of acromegaly

Crinetics (CRNX) Reiterated at Market Outperform by Citizens

Thu, 11 Jun 2026 05:10:29 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $95.00 price target on Crinetics (NASDAQ: CRNX).

The analyst commented, "Camurus' CRL is primarily related to manufacturing so we expect it can be resolved over time, but FDA may need to reinspect its third-party manufacturer and scheduling may result in an even further delay. We view the update as an incremental positive for CRNX; however, we did and do not view Oclaiz as a major competitive threat to Palsonify. Oclaiz is still a monthly injectable SSA and has advantage of self-administration over approved injectables but is still an injection, and we

Crinetics launches patient advocacy program for endocrine diseases

Tue, 02 Jun 2026 16:05:40 -0400

Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) announced the launch of Everyday Advocacy, an initiative to support patient education and self-advocacy within endocrine disease communities.

The program provides digital resources, educational workshops, and tools designed to help patients navigate healthcare interactions. A steering committee comprising five patient advocacy organizations will guide the initiative, including Acromegaly Community, CARES Foundation, Cushing's Support & Research Foundation, Neuroendocrine Cancer Foundation, and Pituitary World News.

Key components include digital tools such as the Acromegaly Symptom Diary mobile app for tracking symptoms, online and in-person workshops for peer connection and healthcare navigation, and ongoing partnerships with patient advocacy organizations.

The platform

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

Tue, 02 Jun 2026 16:05:00 -0400

Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions

Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the launch of Everyday Advocacy, a new initiative designed to support patient education, self-advocacy, and connection within endocrine disease communities.

“Crinetics is led by a conviction that meaningful progress for endocrine disease treatment

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

Tue, 02 Jun 2026 16:05:00 -0400

Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions

Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs

“Crinetics is led by a conviction that meaningful progress for endocrine disease treatment

Form 4 Crinetics Pharmaceutical For: May 29 Filed by: Struthers Richard Scott

Tue, 02 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26591475.html

Form 4 Crinetics Pharmaceutical For: May 29 Filed by: Struthers Richard Scott

Tue, 02 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26591475.html

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Tue, 02 Jun 2026 04:55:00 -0400

Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals

Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing’s syndrome study

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that data from six abstracts, including oral presentations featuring PALSONIFY™ (paltusotine) and investigational candidate

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Tue, 02 Jun 2026 04:55:00 -0400

Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

Fri, 22 May 2026 16:05:00 -0400

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY.

Management will be available for 1x1 meetings with investors on Wednesday, June 3, 2026. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

Fri, 22 May 2026 16:05:00 -0400

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 15 May 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260515/26501337.html

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 15 May 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260515/26501337.html